Fig. 3.

The ability of the nonselective Bn analog agonist (Peptide-1) (A) and the BRS-3–selective peptide antagonist Bantag-1 (B) to inhibit the binding of either ligand to cells containing BRS-3, GRPR, or NMBR. BALB 3T3 cells stably transfected with hBRS-3 (1 × 10⁶ cells/ml), hGRPR (0.5 × 10⁶ cells/ml), or hNMBR (0.05 × 10⁶ cell/ml) were incubated with 50 pM ¹²⁵I-Peptide-1 for 60 minutes at 22°C, and the saturable binding was determined as described in Materials and Methods. The results are expressed as the percentage of saturable binding without unlabeled peptide added (percentage control). The results are the mean and S.E.M. from at least three separate experiments, and in each experiment the data points were determined in duplicate. BALB, BALB 3T3 cells. For other abbreviations, see the Fig. 1 legend.